Trial · NCT04696055
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Up to 15 months (primary outcome as previously reported) | 5.9 | 95% Confidence Interval 1.6 to 14.4 | Percentage of participants |
| Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Up to 15 months (primary outcome as previously reported) | 11.1 | 95% Confidence Interval 2.4 to 29.2 | Percentage of participants |
| Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Up to 38 months (as of study completion) | 7.4 | 95% Confidence Interval 2.4 to 16.3 | Percentage of participants |
| Overall Response Rate (ORR) Per RECIST 1.1 by Central Assessment | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Up to 38 months (as of study completion) | 14.8 | 95% Confidence Interval 4.2 to 33.7 | Percentage of participants |
| Overall Response Rate (ORR) Per RECIST 1.1 by Investigator Assessment | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | 7.4 | 95% Confidence Interval 2.4 to 16.3 | Percentage of participants | |
| Overall Response Rate (ORR) Per RECIST 1.1 by Investigator Assessment | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | 18.5 | 95% Confidence Interval 6.3 to 38.1 | Percentage of participants | |
| Duration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Central assessment | 210 | Full Range 158 to 937 | Days |
| Duration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Central assessment | 195 | Full Range 83 to 280 | Days |
| Duration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Investigator assessment | 431 | Full Range 82 to 893 | Days |
| Duration of Response (DOR) Per RECIST 1.1 by Central Assessment and Investigator Assessment | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Investigator assessment | 364 | Full Range 117 to 839 | Days |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Any TEAE | 68 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Any TEAE | 27 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Any SAE | 37 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Any SAE | 11 | Participants | |
| Number of Participants With Safety-relevant Changes in Clinical Parameters | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | 0 | Participants | ||
| Number of Participants With Safety-relevant Changes in Clinical Parameters | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | 0 | Participants | ||
| Percentage of Participants With Dose Modification | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Regorafenib - drug interruptions or delays | 63.2 | Percentage of participants | |
| Percentage of Participants With Dose Modification | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Regorafenib - drug interruptions or delays | 70.4 | Percentage of participants | |
| Percentage of Participants With Dose Modification | Cohort 1 (Regorafenib + Pembrolizumab [1L: Atezolizumab + Bevacizumab]) | Regorafenib - dose reductions | 41.2 | Percentage of participants | |
| Percentage of Participants With Dose Modification | Cohort 2 (Regorafenib + Pembrolizumab [1L: Any Other IO Containing Treatment]) | Regorafenib - dose reductions | 63.0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04696055/results